Instruction for use: Zveroboi

Dosage form: tablets

Active substance: Deerslayer perforated herb extract (Hyperici perforati herbae extract)

ATX

A13A Tetanus preparations

Pharmacological groups:

Antidepressants

Sedatives

The nosological classification (ICD-10)

F41.2 Mixed anxiety and depressive disorder: Depression with anxiety-depressive components; Mixed anxiety-depressive conditions; Anxiety Depression; Anxious and depressing mood; Anxiety-depressive state; Anxious-depressive conditions; Anxiety-depressive syndrome; Anxious-Neurotic Conditions

F48.9 Neurotic disorder, unspecified: Neurosis; Secondary neurotic symptom; Other neurotic conditions; Neurosis with increased irritability; Neuroses; Neuroses of all kinds; Neuroses with retardation; Neuroses of the heart; Neurotic disorders in alcoholism; Neurotic disorders with retardation; Neurotic disorders with anxiety syndrome; Neurotic reactions; Neurotic symptoms with alcoholism; Neurotic states; Neurotic syndrome; Neurotic disorder; Attack of neurological dysfunction; School neurosis; Emotional Stress

N95.1 Menopausal and climacteric conditions in women: Atrophy of the mucous membrane of the lower sections of the genito-urinary tract caused by estrogen deficiency; Vaginal dryness; Vegetative disorders in women; Hypoestrogenic conditions; Estrogen deficiency in women in menopause; Dystrophic change in the mucous membrane in menopause; Natural menopause; Intact uterus; Climax; Men's Climax; Menopause in women; Menopause Depression; Menopause dysfunction; Climacteric neurosis; Menopause; The climacteric period complicated by psycho-vegetative symptoms; Menopausal Symptom Complex; Climacteric vegetative disorder; Climacteric psychosomatic disorder; Menopause in women; Menopausal vascular disorder; Menopausal vasomotor symptoms; Insufficiency of estrogens; Feeling of heat; Pathological menopause; Perimenopause; Menopause Period; Post-menopausal period; The postmenopausal period; Postmenopausal period; Premature menopause; Premenopause; Premenopausal period; Tides; Hot flushes; Blood flashes to the face in meno- and post-menopause; Hot flushes / sensations in menopause; Heartbeat during menopause; Early menopause in women; Disorders in menopause; Menopause syndrome; Vascular complications of climacteric period; Physiological menopause; Estrogen-deficient conditions; Menopause premature

R45.3 Demoralization and apathy: Apatiko-Abulian phenomenon; Apathy; Apatobulic conditions; Apathoabulic Disorder; Apatobulic state; Indifference; Bezynitsiativnost; Vyaloapaticheskoe condition; Sluggish-apathic state; Deficiency of motivations and motivations; Lack of initiative; Lack of emotionality and avoidance of communication; Feeling of inferiority; Decreased initiative; Decreased motivation; Reduced initiative

Composition and release form

Tablets - 1 table.

St. John's wort extract 200 mg dry

auxiliary substances: lactose; corn starch; magnesium stearate

in contour cell or cell-free packaging 2, 4, 6, 8, 10 or 12 pcs .; in a pack of cardboard 1, 2, 3, 4 or 5 packages.

Description of dosage form

Round flat, with a bevelled edge of the tablet, from gray to brown with lighter and darker patches, with a specific odor. On both sides of the engraving "NP" against the background of the tree.

Characteristic

Means of plant origin.

Pharmachologic effect

Mode of action - antidepressant.

Pharmacodynamics

Has a beneficial effect on the functional state of the central nervous system and the autonomic nervous system.

The drug has a mild anxiolytic (eliminates the feeling of fear and tension) and antidepressant (eliminates depression and apathy) action, increases mental and physical activity, normalizes sleep.

Indications of the drug Zveroboi

psycho-vegetative disorders (depression of mood, apathy, etc.);

depressive conditions of mild and moderate severity, accompanied by anxiety (including those associated with climacteric syndrome, weather change);

neurotic reactions.

Contraindications

individual hypersensitivity to the components of the drug;

severe endogenous depression;

photodermatitis (including in the anamnesis);

pregnancy;

the period of breastfeeding;

children under 12 years.

Side effects

From the digestive system: nausea, abdominal pain (including in the epigastric region), dry mouth, flatulence, diarrhea or constipation, anorexia.

On the part of the organs of hematopoiesis: iron deficiency anemia.

Allergic reactions: reddening and itching of the skin, the appearance of rashes, etc .; photosensitization (more often in HIV-infected patients).

Also, in some cases, you may experience a feeling of fatigue, headache, mild anxiety.

Interaction

Do not take the drug simultaneously with MAO inhibitors (the interval between taking these drugs should be at least 14 days); cyclosporin, indinavir and other protease inhibitors. It is not recommended simultaneous reception with drugs containing ethinyl estradiol and desogestrel. It should not be taken concomitantly with alcohol.

Increases the activity of enzymes involved in the metabolism of drugs, including. within 2 weeks after cancellation, and lowers the concentration in the plasma and the effect of warfarin, theophylline, digoxin, oral contraceptives, reserpine.

Increases the side effects of tryptane derivatives and antidepressants that inhibit serotonin reuptake (fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram).

The drug is able to enhance the photosensitizing effect of other drugs: tetracyclines, sulfonamides, thiazide diuretics, quinolones, piroxicam, etc. Lengthens sleep caused by drugs for general anesthesia and narcotic analgesics, but shortens sleep caused by barbiturates.

Dosing and Administration

Inside, 1-2 table. 3 times a day. The course of treatment - at least 3 weeks. Without consulting a doctor, the duration of the subsequent application should not exceed 3 months.

Special instructions

There is no data on the effect of the drug on the performance of potentially hazardous activities requiring increased concentration of attention and speed of psychomotor reactions (including motor vehicle management), however, the use of the drug in these cases is not recommended. During the administration of the drug, UV exposure should be avoided (prolonged exposure to sunlight).

Storage conditions for Zveroboi

In a dry, the dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life of Zveroboi

3 years.

Do not use after the expiry date printed on the package.